Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy

Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy

In the last three years, five novel treatments have been shown to improve survival in metastatic castration-resistant prostate cancer (CRPC). These novel treatments have distinct mechanisms of action: tubulin-binding chemotherapy (cabazitaxel); immunotherapy (sipuleucel-T); CYP-17 inhibition (abirat...

Full description

Bibliographic Details
Main Authors:	Aurelius Omlin, Carmel Pezaro, Silke Gillessen Sommer
Format:	Article
Language:	English
Published:	SAGE Publishing 2014-02-01
Series:	Therapeutic Advances in Urology
Online Access:	https://doi.org/10.1177/1756287213509677

Similar Items

In-depth Analysis of the 2019 Advanced Prostate Cancer Consensus Conference: The Importance of Representation of Medical Specialty and Geographic Regions
by: Manolis Pratsinis, et al.
Published: (2021-04-01)

PARP inhibitor combinations in prostate cancer
by: Carmel Pezaro
Published: (2020-03-01)

Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer
by: Prestwich Robin, et al.
Published: (2011-06-01)

ATM/NEMO signaling modulates the expression of PD-L1 following docetaxel chemotherapy in prostate cancer
by: Lan Shao, et al.
Published: (2021-07-01)

Prediction for survival following docetaxel-based chemotherapy in Taiwanese men with castration-resistant metastatic prostate cancer
by: Kai-Fu Yang, et al.
Published: (2015-12-01)

Sequential Docetaxel in ≥7 Cycles Followed by Cabazitaxel Improves Oncological Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer
by: Seiichi Kato, et al.
Published: (2021-01-01)

CXCR4 Inhibition with AMD3100 Sensitizes Prostate Cancer to Docetaxel Chemotherapy
by: Urszula M. Domanska, et al.
Published: (2012-08-01)

Weekly-docetaxel chemotherapy for Taiwanese patients withmetastatic castrate-resistant prostate cancer
by: Cheng-Li Kao, et al.
Published: (2015-06-01)

Prostate-specific antigen testing in men with metastatic castration-resistant prostate cancer treated with docetaxel chemotherapy
by: Yuh-Shyan Tsai, et al.
Published: (2015-12-01)

Impact of comorbidity on the outcome in men with advanced prostate cancer treated with docetaxel
by: Zist Andrej, et al.
Published: (2015-12-01)

Concomitant chemoradiotherapy with docetaxel and cisplatin followed by consolidation chemotherapy in locally advanced unresectable non-small cell lung cancer
by: Celalettin Eroglu, et al.
Published: (2013-01-01)

Early Response of Prostate Carcinoma Xenografts to Docetaxel Chemotherapy Monitored With Diffusion MRI
by: Dominique Jennings, et al.
Published: (2002-01-01)

Identification of biomarkers, pathways and potential therapeutic target for docetaxel resistant prostate cancer
by: Rui-ji Liu, et al.
Published: (2021-01-01)

Association of body composition with outcome of docetaxel chemotherapy in metastatic prostate cancer: a retrospective review.
by: Weixin Wu, et al.
Published: (2015-01-01)

Treatment sequencing in metastatic castrate-resistant prostate cancer
by: Oliver Sartor, et al.
Published: (2014-06-01)

Development and clinical testing of individual immunoassays for the quantification of serum glycoproteins to diagnose prostate cancer.
by: Kathrin Endt, et al.
Published: (2017-01-01)

Neoadjuvant docetaxel treatment for locally advanced prostate cancer: A clinicopathologic study
by: M. Berkut, et al.
Published: (2020-11-01)

Docetaxel in hormone-sensitive advanced prostate cancer; GENESIS-SEFH evaluation reporta
by: Emilio Jesús Alegre del Rey, et al.
Published: (2017-07-01)

Potential use of Aneustat for improvement of docetaxel-based therapy of advanced prostate cancer
by: Qu, Sifeng
Published: (2017)

Complete remission in very advanced oral cancer by docetaxel, cisplatin, 5-fluorouracil based induction chemotherapy followed by concurrent chemoradiation
by: Tien-En Chiang, et al.
Published: (2018-03-01)

Undifferentiated prostate cancer treated with docetaxel
by: Masaki Kobayashi, et al.
Published: (2020-07-01)

Metastatic Prostatic Ductal Adenocarcinoma Successfully Treated with Docetaxel Chemotherapy: A Case Report
by: Ryo Fujiwara, et al.
Published: (2015-08-01)

Disseminated Intravascular Coagulation as an Initial Manifestation of Metastatic Prostate Cancer Emergently Treated with Docetaxel-Based Chemotherapy
by: Kavita Agrawal, et al.
Published: (2019-01-01)

Cisplatin and Fluorouracil Induction Chemotherapy With or Without Docetaxel in Locoregionally Advanced Nasopharyngeal Carcinoma
by: Ting Jin, et al.
Published: (2019-04-01)

Periungual lesions secondary to chemotherapy with docetaxel
by: Dawid Sigorski, et al.
Published: (2020-02-01)

Clinical outcome and predictive factors for docetaxel and epirubicin neoadjuvant chemotherapy of locally advanced breast cancer
by: Hye Sung Won, et al.
Published: (2020-11-01)

Effect of the preoperative docetaxel combined with S-1 chemotherapy on the oncogene expression in advanced gastric cancer lesion
by: E-Yi Ben, et al.
Published: (2017-11-01)

Gleason score and docetaxel response in advanced hormone-sensitive prostate cancer: The lower the better
by: Omer Dizdar, et al.
Published: (2019-08-01)

Dose-Dense Epirubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Chemotherapy in Node-Positive Breast Cancer
by: Hamid Reza Mirzaei, et al.
Published: (2013-01-01)

Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space
by: Sartor A Oliver
Published: (2011-04-01)

Molecular Profiling of Docetaxel-Resistant Prostate Cancer Cells Identifies Multiple Mechanisms of Therapeutic Resistance
by: Thiago S. Lima, et al.
Published: (2021-03-01)

Docetaxel in the treatment of hormone-resistant prostate cancer
by: B. V. Bukharkin, et al.
Published: (2020-02-01)

Concurrent chemoradiotherapy with low-dose weekly docetaxel followed by consolidation chemotherapy with docetaxel and cisplatin in the treatment of stage III non-small cell lung cancer
by: Tianlin XIAO, et al.
Published: (2008-02-01)

Efficacy of Androgen Deprivation Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel-Based Chemotherapy
by: Kyungchan Min, et al.
Published: (2020-04-01)

Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel risk stratification model in castration-resistant prostate cancer patients treated with docetaxel chemotherapy
by: Yoshihiro Nakagami, et al.
Published: (2015-06-01)

Clinical benefits of combined chemotherapy with S-1, oxaliplatin, and docetaxel in advanced gastric cancer patients with palliative surgery
by: Liu Y, et al.
Published: (2016-03-01)

Bevacizumab and Weekly Docetaxel in Patients with Metastatic Castrate-Resistant Prostate Cancer Previously Exposed to Docetaxel
by: Filippo Francini, et al.
Published: (2011-01-01)

Successful Treatment of Advanced Metastatic Prostate Cancer following Chemotherapy Based on Molecular Profiling
by: Charles E. Myers, et al.
Published: (2012-03-01)

Life-Threatening Pneumonitis Related to Docetaxel Chemotherapy
by: Mei-Kim Ang MBBCh, MRCP, et al.
Published: (2015-03-01)

Effects of docetaxel combined with platinum drugs and S-1 chemotherapy on cancer cell growth in advanced gastric cancer lesions
by: Xiong Zhang, et al.
Published: (2017-06-01)